Nicotinium methane sulfonate (NMS): A bio-renewable protic ionic liquid and bi-functional catalyst for synthesis of 2-amino-3-cyano pyridines
-
Add time:08/09/2019 Source:sciencedirect.com
In this work, a simple approach was used to quantitative preparation of nicotinum methane sulfonate (1-methyl-2-(pyridin-3-yl)pyrrolidin-1-ium methanesulfonate (NMS)) from nicotine and methane sulfonic acid. NMS, as a novel, mild, efficient, economic, and task-specific ionic liquid (TSIL) with dual acid and base functional groups, has been characterized by NMR, FT-IR, acidity measurements, and elemental analysis. This protic ionic liquid shows excellent catalytic activity in one-pot synthesis of 2-amino-3-cyanopyridines in 78–98% from malononitrile, aromatic aldehydes, methyl ketones, and ammonium acetate under solvent-free conditions. NMS is a nature-based recyclable and reusable catalyst.
We also recommend Trading Suppliers and Manufacturers of 2-Cyano-4-(pyrrolidin-1-yl)pyridine (cas 127680-86-8). Pls Click Website Link as below: cas 127680-86-8 suppliers
Prev:On the reaction of 2-[(4-cyano-5,6,7,8-tetrahydroisoquinolin-3-yl)oxy]acetamides with bases: 1-amino-6,7,8,9-tetrahydrofuro[2,3-c]isoquinoline-2-carboxamides and 3-amino-4-cyano-5,6,7,8-tetrahydroisoquinolines via a Smiles-type rearrangement
Next:Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Synthesis, biological evaluation and molecular modeling of imidazo[1,2-a]pyridine derivatives as potent antitubulin agents08/11/2019
- Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes08/10/2019
- On the reaction of 2-[(4-cyano-5,6,7,8-tetrahydroisoquinolin-3-yl)oxy]acetamides with bases: 1-amino-6,7,8,9-tetrahydrofuro[2,3-c]isoquinoline-2-carboxamides and 3-amino-4-cyano-5,6,7,8-tetrahydroisoquinolines via a Smiles-type rearrangement08/08/2019


